Market capitalization | $27.48m |
Enterprise Value | $27.49m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.57 |
P/S ratio (TTM) P/S ratio | 1.57 |
P/B ratio (TTM) P/B ratio | 1.50 |
Revenue growth (TTM) Revenue growth | 1.33% |
Revenue (TTM) Revenue | $17.55m |
As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.
2 Analysts have issued a ImmunoPrecise Antibodies Ltd forecast:
2 Analysts have issued a ImmunoPrecise Antibodies Ltd forecast:
Jan '25 |
+/-
%
|
||
Revenue | 18 18 |
1%
1%
|
|
Gross Profit | 8.92 8.92 |
1%
1%
|
|
EBITDA | -8.71 -8.71 |
9%
9%
|
EBIT (Operating Income) EBIT | -11 -11 |
13%
13%
|
Net Profit | -34 -34 |
223%
223%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.
Head office | Canada |
CEO | Jennifer Bath |
Employees | 87 |
Founded | 1983 |
Website | www.ipatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.